Best Genomics Companies in China
The 263 best Genomics companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MGI.
China's Genomics sector has $6.9B in disclosed funding spread across 263 tracked companies, and the gap between leaders and the rest is stark. Singlera Genomics sits at $209M, with RONA Therapeutics at $68M and Epigenic Therapeutics at $52M rounding out the top tier. The global market was valued at roughly $24.3B in 2021 and is forecast to reach $85.1B by 2030 at a 16.37% CAGR, driven by falling sequencing costs and a genuine shift toward personalized medicine. That trajectory matters for you if you're sizing up where Chinese capital is concentrating right now.
So what's the actual momentum story? Hot themes this quarter are hereditary disease genomics, machine learning drug discovery, and pharmacogenomics, and the most active investors, Qiming Venture Partners, CD Capital, and CDH, are all leaning in. I'd flag that there are still zero unicorns in this cohort despite the funding scale, which tells you valuation discipline is real here. Dr. Lal Pathlabs eyeing genomics M&A and Mukesh Ambani calling genomics a pillar of India's next era both signal that regional conviction around this sector is building fast, and China's companies are right at the center of that wave.
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in China
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MGI Provider of gene sequencing instruments, reagents, equipment, and related products | $1.0B | 72 mo ago | Series B | 2,805 | 2016 | PHPAnimate.cssThinkPHP+6 | 19 patents Integrated microfluidic sequencing devices with temperature control, reagent cartridges, and chemiluminescent reagents | — |
| 2 | 3DMed Provider of personalized diagnostic treatment solutions for cancer | $365M | 67 mo ago | Series D | 215 | 2010 | — | — | — |
| 3 | BGI Provider of services in genome sequencing | $300M | 63 mo ago | Public | 7 | 1999 | HubSpot CMS HubEnvoyHubSpot+10 | — | 1 launch · 1 partnership |
| 4 | Sangon Biotech Provider of research services and reagents and kits | $300M | 37 mo ago | Series B | 951 | 2003 | — | — | — |
| 5 | Genecast Non-invasive diagnosis and monitoring of cancer | $246M | 67 mo ago | Series E | — | 2014 | — | — | 1 job opening · 1 partnership |
| 6 | Guangzhou Kang Liming Biotechnology Provider of cancer detection kits | $220M | 56 mo ago | Series D | — | 2015 | — | — | — |
| 7 | Singlera Genomics Developer of the NGS-based platform to detect cancer 72Moat top 21%Funding top 26%Market top 30%Patents top 33% All 6 signals ▾Moattop 21% Fundingtop 26% Markettop 30% Patentstop 33% Innovationtop 41% Globalbottom 40% Moat: Editorial + unicorn rating 8/10 · IP moat: 29 patents Funding: Raised $209M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $209M | 23 mo ago | Series B | 300 | 2014 | — | 29 patents Liquid biopsy DNA methylation biomarkers for cancer detection and tumor assessment | — |
| 8 | Siwei Biotechnology Developer of nanocarrier delivery platform for mRNA vaccines | $206M | 60 mo ago | Deadpooled | — | 2016 | — | — | — |
| 9 | Burning Rock Developer of personalised diagnostic and treatment services based on genomic big data analysis | $203M | 88 mo ago | Public | 1,138 | 2014 | — | 42 patents Cancer genomics diagnostics: tumor risk assessment, mutation and copy-number detection, bioinformatics tools. | — |
| 10 | Souzhou Ribo Life Science Developer of nucleic acid drugs based on RNA interference (RNAi) technology | $201M | 46 mo ago | Public | 228 | 2007 | — | — | — |
| 11 | Qi Carbon Technology Developer of single-molecule nanopore sequencing technology 48Moat top 22%Funding top 27%Talent top 41%Growth top 45% All 7 signals ▾Moattop 22% Fundingtop 27% Talenttop 41% Growthtop 45% Markettop 46% Techbottom 34% Globalbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $187M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $187M | 29 mo ago | Series C | 270 | 2016 | Node.jsJavaUbuntu+7 | — | — |
| 12 | EdiGene Developer of genome editing technology for the treatment of cancer and genetic disease | $165M | 61 mo ago | Series B | 140 | 2015 | — | 103 patents Patents concentrated in chemistry & materials | — |
| 13 | GeneMind Developer of genome sequencing technology for molecular diagnosis | $158M | 34 mo ago | Series C | — | 2012 | WordPressMySQLPHP+17 | — | 1 launch |
| 14 | Zhejiang Nuhui Health Technology Provider of early cancer screening and testing services | $152M | 71 mo ago | Public | 1,041 | 2013 | — | — | — |
| 15 | Bluepha Developer of synthetic biology and biomaterial | $133M | 40 mo ago | Series B | 120 | 2016 | — | — | — |
| 16 | Geneseeq Geneseeq is an industry leader in next-generation sequencing (NGS) fully committed to the research and… | $128M | 77 mo ago | Series D | 1,345 | 2013 | WordPressMySQLPHP+19 | — | — |
| 17 | Weiyuan Gene Provider of gene editing and sequencing technology for precision medicine | $121M | 54 mo ago | Series D | — | 2018 | — | — | — |
| 18 | NeoCura Provider of an AI-enabled immunotherapy based tumor diagnostic platform | $117M | 53 mo ago | Series A | — | 2017 | — | — | — |
| 19 | Qixin Biotechnology Provider of gene-editing technology for therapies | $116M | 32 mo ago | Series A | — | 2017 | Apple iCloud MailNode.jsVue.js+6 | — | — |
| 20 | BerryOncology Developer of gene sequencing products for disease diagnostics | $108M | 58 mo ago | Series B | — | 2017 | — | — | — |
| 21 | Xbiome Developer of an AI-enabled bioinformatics platform for the discovery of drugs using intestinal microbiome 64AI top 20%Funding top 36%Moat top 38%Market top 49% All 5 signals ▾AItop 20% Fundingtop 36% Moattop 38% Markettop 49% Globalbottom 36% AI: Classified as an AI company Funding: Raised $108M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $108M | 53 mo ago | Series B | 63 | 2017 | — | — | — |
| 22 | Xiantong Pharmaceutical Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases and cardiovascular… | $100M | 35 mo ago | Series E | 400 | 2004 | — | — | — |
| 23 | Innovative Cellular Therapeutics Developer of CAR-T cell therapies for blood cancers and solid tumors | $97M | 57 mo ago | Series C | 14 | 2009 | — | 73 patents Engineered immune cells for adoptive cell therapy targeting tumor antigens | — |
| 24 | CureGenetics Provider of CRISPR-Cas9 based gene-editing technology for therapy and diagnosis | $79M | 53 mo ago | Series B | 17 | 2016 | — | — | — |
| 25 | HeliXon Developer of an integrated platform for protein therapeutic discovery and optimization | $75M | 47 mo ago | Series A | — | 2009 | — | — | — |
| 26 | AnchorDx Developer of high throughput gene sequencing platform for clinical application | $73M | 63 mo ago | Series C | 20 | 2015 | — | — | — |
| 27 | RONA Therapeutics Developer of oligonucleotide therapeutics to treat multiple diseases 40Patents top 31%Moat top 32%Funding top 40%Innovation top 42% All 7 signals ▾Patentstop 31% Moattop 32% Fundingtop 40% Innovationtop 42% Talentbottom 49% Globalbottom 43% Marketbottom 40% Patents: 27 patents matched (strict assignee match) · 27 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 27 patents rank vs industry peers · Fliar Intelligence Index 40/100 | $68M | 23 mo ago | Series A | — | 2021 | — | 27 patents RNAi therapeutics and targeted siRNA/ dsRNA delivery for disease-modifying gene regulation | — |
| 28 | Ustar Biotechnologies Isothermal amplification kits for pathogen detection and genotyping of infectious diseases | $62M | 54 mo ago | Series E | 65 | 2005 | WordPressMySQLPHP+21 | 31 patents Integrated microfluidic nucleic acid detection platforms for rapid CRISPR‑based diagnostics | — |
| 29 | CircleDNA Provider of internet first diagnostics platform for genetic tests | $60M | 69 mo ago | Series B | — | 2014 | Cart FunctionalityShopifyAmazon ALB+33 | — | — |
| 30 | Epigenic Therapeutics Developer of gene editing therapies for a wide variety of diseases 57Funding top 26%Patents top 28%Moat top 32%Innovation top 37% All 9 signals ▾Fundingtop 26% Patentstop 28% Moattop 32% Innovationtop 37% AItop 45% Talentbottom 49% Newsbottom 42% Marketbottom 40% Globalbottom 40% Funding: Raised $52.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Patents: 43 patents matched (strict assignee match) · 43 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $52M | 9 mo ago | Series B | — | 2021 | — | 43 patents Epigenome editing tools for therapeutic gene repression (viral, metabolic, angiogenesis targets). | — |
| 31 | Murren Biotechnology Developer of microbial separation and cultivation technologies 40Moat top 22%Funding top 38%Market top 48%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 38% Markettop 48% Talentbottom 49% Globalbottom 29% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $50.6M across 2 rounds · 2 rounds over 8 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $51M | 23 mo ago | Series C | 50 | 2015 | — | — | — |
| 32 | Guangzhou Jia inspection medical testing Provider of diagnostic testing services for genetic analysis | $50M | 48 mo ago | Series B | 63 | 2015 | — | — | — |
| 33 | Health Gene Technologies Provider of DNA testing solutions for diagnostic solutions | $48M | 46 mo ago | Series C | 33 | 2011 | — | — | — |
| 34 | Zhengxu Biotechnology Developer of gene-editing technology to treat genetic diseases | $47M | 55 mo ago | Series C | — | 2020 | BootstrapNginxModernizr+5 | — | — |
| 35 | Zhuhai Shengmei Biodiagnostic Technology Developer of liquid biopsy-based lung cancer diagnostic technology | $46M | 62 mo ago | Series B | 59 | 2019 | — | — | — |
| 36 | Haplox Provider of ultra sensitive liquid biopsy tests for cancer | $39M | 46 mo ago | Series D | 724 | 2014 | Node.jsTailwind CSSVue.js+5 | — | — |
| 37 | Sniper Developer of droplet digital PCR | $31M | 56 mo ago | Series B | — | 2018 | — | — | — |
| 38 | Beijing Rubber Xin Biological Technology Developer of tumor genetic testing reagents and instruments | $29M | 41 mo ago | Series B | — | 2017 | — | — | — |
| 39 | Shanghai Zhongke New Life Biological Technology Provider of sequencing and bioinformatics services | $28M | 26 mo ago | Series C | 90 | 2003 | — | — | — |
| 40 | Beijing Zhongyin Technology Digital clinical genetic diagnosis tool for providers 42Funding top 41%Talent bottom 45%Global bottom 29% All 3 signals ▾Fundingtop 41% Talentbottom 45% Globalbottom 29% Funding: Raised $26.5M · 3 rounds over 5 yrs (0.6/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 42/100 | $26M | 32 mo ago | Series A | — | 2015 | — | — | — |
| 41 | Hangzhou Lianchuan Biotechnology Provider of genetic testing services | $26M | 56 mo ago | Series B | 271 | 2006 | — | — | — |
| 42 | Zhangjiagang Wanzhongyixin Biological Technology Developer of bio-detection chips and electronic biochemical sensors | $24M | 32 mo ago | Series B | 80 | 2014 | — | — | — |
| 43 | Beijing Xinyi Biotechnology Manufacturer of micro-droplet digital PCR and in vitro diagnostic reagents | $23M | 27 mo ago | Series B | — | 2015 | — | — | — |
| 44 | Dynamic BioSystems Developer of technologies for multi-omics single-cell analysis | $20M | 40 mo ago | Deadpooled | 150 | 2021 | — | — | — |
| 45 | Huida Developer of gene therapies for the treatment of multiple disease conditions | $19M | 49 mo ago | Series C | 150 | 2018 | PHPanime.jsAnimate.css+5 | 2 patents Anti‑freeze water‑pipe valves and theft‑resistant fastening screws. | — |
| 46 | ThunderBio Innovation Developer of microfluidic technology for diagnosis and research | $15M | 29 mo ago | Series B | — | 2018 | — | — | — |
| 47 | YolTech Developer of gene editing and LNP delivery platforms for therapeutics 27Funding top 37%Moat top 42%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 37% Moattop 42% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $14.1M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 27/100 | $14M | 9 mo ago | Series B | — | 2021 | — | — | — |
| 48 | Milestone Biotechnologies Company solutions for various applications including single-cell mutation analysis, CDMO services and… 24Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 36% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $13.6M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $14M | 17 mo ago | Series A | — | 2014 | — | — | — |
| 49 | GenEditBio Provider of gene editing-based solutions for genetic diseases | $10M | 20 mo ago | Seed | — | 2021 | Microsoft ASP.NETTengineModernizr+2 | 26 patents Therapeutic CRISPR gene editing delivery via engineered proteins and lipid nanoparticles | — |
| 50 | Bai Kui Rui Provider of synthetic biology platform to treat various diseases | $8M | 25 mo ago | Series A | — | — | — | — | — |
Top 12 Genomics companies in China
#1
Series B · Shanghai, Shanghai · founded 2021$52Mraised▾
Developer of gene editing therapies for a wide variety of diseases. The company uses proprietary and patented technology platform Artificial intelligence (AI) algorithms and lipid nanoparticle (LNP) medicine delivery system to deliver medicine to target cells and tissues ex vivo and in vivo in ocular, neurodegeneration, metabolic, and rare disease models.
- Sep 2025Series B$60M
- Aug 2023Series A$32M
- Aug 2022Seed$20M
#2
Series B · Shanghai, Shanghai · founded 2021$14.1Mraised▾
Developer of gene editing and LNP delivery platforms for therapeutics. It focuses on creating novel tools for genome editing using metagenomics data. It develops in vivo gene-editing medicines for genetic, metabolic, cancer, and cardiovascular diseases. It is researching treatments for diseases such as familial hypercholesterolemia and hereditary transthyretin amyloidosis.
- Sep 2025Series B$45M
- Nov 2023Series A$14.1M
- Feb 2022Angel—
- Series A—
#3
Series B · Pudong, Shanghai · founded 2014 · 300 employees$208.6Mraised▾
Developer of the NGS-based platform to detect cancer. The company has methylation haplotyping technology for detecting cancer biomarkers. Tumor cells release circulating tumor DNA (ctDNA) into the blood when undergoing apoptosis or necrosis and this ctDNA is detected as cancer biomarkers. The company has developed a PanSeer assay that measures distinct tumor-specific methylation patterns in adjacent methylation sites. It can detect cancer up to four years before conventional diagnosis.
- Jul 2024Series B$13.8M
- Jun 2022Series B$44.9M
- Dec 2020Series B$150M
- 2018Series A—
#4
Series A · Shanghai, Shanghai · founded 2021$68Mraised▾
Developer of oligonucleotide therapeutics to treat multiple diseases. The company focuses on the discovery and development of modular and programmable RNA medicines targeting disease areas across metabolic diseases, neurological diseases, and ophthalmology diseases by using proprietary delivery systems.
- Jul 2024Series A$35M
- Apr 2022Series A$33M
#5
Series C · Beijing, Beijing · founded 2015 · 50 employees$50.6Mraised▾
Developer of microbial separation and cultivation technologies. It has developed Eco-screening TM technology, fungal high-density solid fermentation technology foroxygen, H2O, pH value, carbon, & nitrogen source, and microfilm coating technology on the surface of seeds to stop the damage of microorganisms. It has applications in biological agriculture, human microbiome research biomedicine, and gene discovery.
- Jul 2024Series C$41.3M
- Feb 2020Series B—
- Jun 2018Seed$9.3M
#6
Series A · Pudong, Shanghai · founded 2014$13.6Mraised▾
Company solutions for various applications including single-cell mutation analysis, CDMO services and agriculture. It specializes in the production and supply of various biological products, including single-cell mutation analysis, PBMC and immune cell subtypes, animal liver cells, and in vivo and in vitro drug efficacy.
- Jan 2025Series A$13.6M
- Aug 2023Series A—
#7
Series C · Chengdu, Sichuan Sheng · founded 2016 · 270 employees$186.7Mraised▾
Developer of single-molecule nanopore sequencing technology. Genome sequencing has been developed for precision medicine and in the fields of NIPT, IVF, liquid biopsy, newborn examination, genetic disease, rare disease research, and tumor classification.
- Dec 2023Series C—
- Dec 2022Series C$101M
- Jun 2021Series B$62.5M
- May 2020Series A$14.1M
#8
Seed · Hong Kong, Hong Kong · founded 2021$10Mraised▾
Provider of gene editing-based solutions for genetic diseases. The company develops precision gene-editing technology and develop a pipeline of programmable gene therapy products.
- Sep 2024Seed—
- Apr 2024Seed$10M
#9
Series B · Shanghai, Shanghai · founded 2003 · 951 employees$300Mraised▾
Provider of research services and reagents and kits. The company offers services like oligos, genes, and peptides syntheses, DNA and NGS sequencing, protein, antibody, and molecular biology-related services. It also sells PCR, enzyme, and other reagents, ELISA, PCR, and other kits.
- Apr 2023Series B$290M
- Aug 2010Series A$10M
#10
Series A · Hangzhou, Zhejiang · founded 2017$116Mraised▾
Provider of gene-editing technology for therapies. The company uses this platform of genetic engineering for developing tools for organ transplantation and regenerative medicines. It uses CRISPR/Cas9 system as a gene-editing tool.
- Sep 2023Series A$16M
- Mar 2021Series A$67M
- Sep 2019Series A$22.5M
- Jul 2018Series A$7.8M
#11
Series C · Shenzhen, Guangdong Province · founded 2012$158Mraised▾
Developer of genome sequencing technology for molecular diagnosis. The products include high-throughput gene sequencers, single-molecule gene sequencers, kits for non-invasive prenatal screening, preimplantation genetic testing, tumor, and genetic disease diagnosis. The company's technology includes sequencing optical systems, synthetic sequencing chemical systems, and sequencing chips.
- Aug 2023Series C$55.7M
- Sep 2021Series B$63.6M
- Jun 2021Series B$38.7M
#12
Series B · Beijing, Beijing · founded 2016 · 120 employees$133Mraised▾
Developer of synthetic biology and biomaterial. The company has microbial manufacturing technology that helps in developing bio-based products for a broad range of industries, including consumer goods, healthcare, specialty chemicals, agriculture, electronics, and more
- Feb 2023Conventional Debt$73.3M
- Feb 2023Series B$58.6M
- Jan 2022Series B—
- Aug 2021Series B$66.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in China
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,131 China-affiliated papers.
- Chinese Academy of Medical Sciences & Peking Union Medical College436
- Chinese Academy of Sciences315
- Sichuan University311
- Central South University298
- Shanghai Jiao Tong University287
- Gene8→544
- Transcriptome5→408
- Genome10→350
- Disease2→212
- Identification (biology)3→192
- Gene2→729
- Disease2→562
- Cancer4→402
- Mechanism (biology)1→341
- Metabolomics1→205
- Disease2→281
- Mechanism (biology)1→142
- Cancer2→119
- Epigenetics2→63
- Gene1→56
Where bioinformatics is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in China
China bioinformatics patent filing is accelerating — 29 filings from 46 assignees (2018–2025), led by Mobidrop Zhejiang, BGI Shenzhen, Intel; annual filings 1→11.
- Mobidrop Zhejiang6
- BGI Shenzhen5
- Intel4
- LI Yingrui3
- Beijing INST Of Radiation Medici2
- WANG JIAN2
- XIA Yudong2
- MGI TECH2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.